http://www.oncogenex.ca/
http://finance.yahoo.com/q/ks?s=ogxi
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of cancer. The company's lead candidate, OGX-011, is being evaluated in two Phase III clinical trials. OGX-011, which is also known as custirsen sodium, inhibits the production of clusterin, a protein that is over-produced in various types of cancer and in response to a range of cancer treatments, including hormone ablation therapy, chemotherapy, and radiation therapy. Its other product candidates include OGX-427, a Phase II clinical trial product, which is focused on reducing heat shock protein 27. The company's preclinical stage product is OGX-225, an inhibitor of insulin growth factor binding proteins 2 and 5.
